← Every company
Astellas Pharma Inc Lobbying
What Astellas Pharma Inc discloses spending to lobby Congress, and who it pays to do it. Every lobbying firm files quarterly under the Lobbying Disclosure Act, naming its client, its fee and the issues it worked.
ALPMY on carbonthat →Disclosed spend
$1.8M
across every filing on file
Filings
15
Years covered
1
Firms retained
4
What it lobbies about
Health IssuesPharmacyMedicare/MedicaidCopyright/Patent/TrademarkTaxation/Internal Revenue Code
15 filings
Newest year first, and within a year the largest fee first — a filing period is a word rather than a date, so it cannot order itself.
| Period | Lobbying for them | Disclosed |
|---|---|---|
| 20261st Quarter (Jan 1 - Mar 31) | ASTELLAS PHARMA US, INC.Medicare/MedicaidHealth Issues | $590K |
| 20262nd Quarter (Apr 1 - June 30) | ASTELLAS PHARMA US, INC.Medicare/MedicaidHealth Issues | $510K |
| 20262nd Quarter (Apr 1 - June 30) | TARPLIN, DOWNS & YOUNG, LLCHealth Issues | $80K |
| 20262nd Quarter (Apr 1 - June 30) | TARPLIN, DOWNS & YOUNG, LLCHealth Issues | $80K |
| 20261st Quarter (Jan 1 - Mar 31) | TARPLIN, DOWNS & YOUNG, LLCHealth Issues | $80K |
| 20262nd Quarter (Apr 1 - June 30) | THEGROUP DC, LLCHealth IssuesPharmacy | $70K |
| 20261st Quarter (Jan 1 - Mar 31) | THEGROUP DC, LLCHealth IssuesPharmacy | $70K |
| 20262nd Quarter (Apr 1 - June 30) | TIBER CREEK GROUPHealth IssuesMedicare/Medicaid | $60K |
| 20261st Quarter (Jan 1 - Mar 31) | TIBER CREEK GROUPHealth IssuesMedicare/Medicaid | $60K |
| 20261st Quarter (Jan 1 - Mar 31) | TODD STRATEGY GROUPPharmacyHealth Issues | $50K |
| 20262nd Quarter (Apr 1 - June 30) | TODD STRATEGY GROUPHealth IssuesPharmacy | $50K |
| 20261st Quarter (Jan 1 - Mar 31) | JEFFREY J. KIMBELL & ASSOCIATES, INC.Health Issues | $40K |
| 20262nd Quarter (Apr 1 - June 30) | JEFFREY J. KIMBELL & ASSOCIATES, INC.Health Issues | $40K |
| 20262nd Quarter (Apr 1 - June 30) | B HALL STRATEGIES, LLCPharmacy | $30K |
| 20261st Quarter (Jan 1 - Mar 31) | B HALL STRATEGIES, LLCPharmacy | $30K |
A filing reports either the fee paid to a lobbying firm or what a company spent lobbying for itself, never both, so the total is a sum of the two. The client is named as filed, which is often a subsidiary. Lobbying is lawful, disclosed and extremely common — the figure is context, not an accusation.